Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.
The facility will manufacture its Herceptin biosimilar, Tuznue
The transaction as well as the open offer is expected to be completed by June this year.
Suvinys Developers will supply dydrogesterone to Jagsonpal Pharma as per the terms and conditions mentioned in the agreement.
AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
The brand has added a range of exciting new products especially formulated for oily skin.
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
Subscribe To Our Newsletter & Stay Updated
